Chronic organ failure results in progressive and invalidating disease. Function can be replaced by artificial organs or transplantation. Classical artificial organ treatment, by "mechanical" technology, e.g. hemodialysis, hemoperfusion, plasmapheresis, or insulin delivery pumps, has been found to be helpful as surrogates of the genuine organ. The alternative, transplantation, results in more complete replacement of physiological function, but it is still hampered by the limited donor organ availability, surgical morbidity and mortality, and the complications of immune suppression.
It is therefore no surprise that medical science has been on the outlook for a third, intermediate alternative. These are the "hybrid" bio-artificial organs, based on the use of biologically active cells or organelles, but protected from immunological and other aggression by a surrounding semi-porous membrane, permeable for small and middle molecules, but not for immunoglobulins.
Research on hybrid artificial organs can be expected to be more rewarding for organs with a relatively simple function, e.g. pancreatic insulin secretion in diabetes mellitus, or for organs where the classical mechanical replacement has been disappointing, e.g. in liver failure. Some of the most important advances during recent years have been made related to these two organ systems.
Artificial pancreas
Since the detection of insulin by Banting and Best, and the possibility of producing this hormone pharmacologically, not much news has been offered to the diabetic patient (1) . Insulins with a short action range were replaced by slower-acting insulins for the comfort of the patient, and then again by short-acting insulins, because of the unsatisfactory prevention of complications with the slow-acting regimens. Insulin pumps were developed for the administration of short-working insulin by the subcutaneous, intravenous or intraperitoneal route. However, the lack of a reliable, durable glucose sensor made it impossible to obtain satisfactory long-term homeostasis of glycemia.
In view of the relative simplicity of the aim, to obtain acceptable blood glucose levels through adequate doses of insulin, it is not surprising that one of the first successful attempts to develop a bionic artificial organ was in fact with the artificial pancreas, reported by Chick et al. as early as 1975 (2) . After culturing neonatal rat beta cells on bundles of artificial capillaries, these workers first demonstrated adequate in vitro insulin production, comparable to conventional flask cultures (2), and two years later glucose homeostasis after connecting this bionic pancreas to the circulation of diabetic rats (3). This first in vivo experiment lasted 10 hours.
Since then, several corrections have been applied to the primary concept, to improve its efficacy and longevity. The system as it is has several advantages over the alternative therapeutic modalities, besides the protection from rejection: protection from immunological aggression in autoimmune diabetes, automatic adaptation of the insulin secretion to the ambient glucose concentration, and the concomitant secretion of hormones other than insulin, such as glucagon and somatomedin, that may playa role in the fine-tuning of blood glucose concentrations.
Its relative simplicity means this concept can be considered as a test case for other, more complex hybrid systems.
Several problems have been encountered (4):
This paper has been presented in part at the ESAO Annual Meeting, Bologna, September 1990 a) bioincompatibility, either clotting for intra-vascular systems, or inflammation for intra-tissue implants; b) cell viability, with loss of the capacity to secrete adequate quantities of insulin over time; c) glucose and insulin kinetics, resulting in a lag time in insulin secretion in response to changes in glucose concentration. These difficulties were to some extent corrected by changes in the architectural design and concept, by a transition from diffusion chambers and simple capillary fibre systems to U-shaped devices for intravascular use as described by Reach et al. (5) , and polyalginate micro-encapsulated systems for intra-peritoneal injection as described by Sun et al. (6, 7) . Both corrections improve biocompatibility and molecular kinetics.
These corrections have resulted in major progress and hope-giving results but they must nevertheless be considered with some care. When the long-term effect of the implantation of a hybrid pancreas on diabetic complications is studied, control experiments may consist of non-treated animals, resulting in spectacular differences in outcome (8) . Nowadays, however, diabetes is virtually always treated, so comparison with other therapeutic regimens would be more appropriate and would probably not produce such spectacular differences.
Second, the current model of experimental diabetes, which is chemically-induced, either by streptozotocin or alloxan, might be not entirely representative of the auto-immune forms more current in humans. Altman et aI., comparing the effects of hybrid pancreas in streptozotocin-induced and auto-immune diabetes in rats, found worse results in the latter model (9) .
Finally, adequate results on the changes in in vitro insulin secretion in response to acute changes in glucose concentrations in the medium have mainly been obtained with the square wave technique, not with gradual, stepwise increases in glucose concentration, which fits the clinical condition better (5) . To our knowledge, Reach et al. are still the only Authors who successfully tested their device with gradual instead of square wave glucose concentration changes.
The main obstacle in the development of a bionic pancreas for human use seems however to be related to the shift from smaller to larger laboratory animals.
A review of the literature shows mainly satisfactory in vivo results in the rat, with a survival increasing over the years (Tab. I) (3, 6-8, 10-13). Successful results in dogs and primates are scarce and were obtained over short periods -maximum 36 hourswith glycemia tending to rise at the end of the observation period (10, 14) . This is mainly related to the difficulty of obtaining a large enough volume of insulin-secreting cells to maintain long-term glucose homeostasis in large species without exhaustion of the cells. Warnick and Rajotte elegantly demonstrated that at least 5000-6000 islets of Langerhans per kilogram body weight would be needed in the dog for adequate management of diabetes (15) . In humans, even more would be needed. In contrast, 1000-3000 islets are reportedly sufficient per rat (11) . It is also difficult to find the appropriate format for optimum kinetics of glucose and insulin. Chicheportiche and Reach found that insulin release was optimized if the volume of micro-encapsulated islets was reduced (16) . Even the smallest micro-encapsulation, however, was still at least eight times larger than genuine islets in a virtual volume.
A final question that arises is whether long-term contact with foreign insulins produced by animal cells will result in antibody formation, as observed with porcine and bovine insulins on subcutaneous administration. Hybrid cells might also produce other foreign materials that could cause allergic or other immune reactions. The alternative, human insulinoma cells, is also debated, since a number of insulinomas result in autonomous insulin production, independent of glycemia. Nevertheless, experience has been reported with insulinoma-based hybrids, resulting in good correction of diabetes (13) .
In conclusion, major steps forward have been made in the development of a hybrid artificial pancreas, but progress is hampered by the difficulties of maintaining the same yield in larger animals than the rat. Until a satisfactory solution has been found, the final aim, application in humans, will remain difficult.
Artificial liver
The need for an artificial liver is felt even more than for an artificial pancreas, since severe hepatic failure is an acute, life-threatening condition, leading to death within a short time. Moreover, current mechanical approaches, such as hemodialysis, hemofiltration, hemoperfusion and plasma exchange have been disappointing, resulting at best in a temporary improvement of mental status, but not reducing overall mortality. The frustration of people caring for these severely ill patients is illustrated by numerous elusive attempts to combine strategies, e.g. dialysis plus plasmapheresis plus hemoperfusion, still without effect on the prognostic outcome.
The functions expected of a bionic artificial liver far outnumber those of a bio-artificial pancreas: detoxification, elimination of toxins, protein synthesis and other metabolic processes. Consequently for the time being the number of successful attempts to develop a bionic artificial liver is still much more limited than for the pancreas. Nevertheless this possibility is highly appealing, all the more since at least acute fulminant hepatic failure is often followed by complete recovery of liver function, if fatal complications can be held at bay long enough.
Several Authors have evaluated biochemical functions in vitro. The problem is that the liver's metabolic activities are multiple, so that some selection has to be made for follow-up. At best several functions, mostly related to protein synthesis and drug detoxification, can be maintained at a satisfactory level for at least 2 to 16 days (Tab. II) (17) (18) (19) (20) . Nevertheless part of the functional capacity is lost during these experiments.
At least five series of animal experiments have assessed the effect of hybrid artificial liver on survival after experimental liver failure (20) (21) (22) (23) (24) . Treatment with a bionic liver gave a worthwhile improvement in survival. Nevertheless, most treated animals died, albeit apparently later than non-treated animals. Average survival in control groups was 12 hours to 3 days compared with up to five days for treated animals (Tab. III) (20) (21) (22) (23) (24) . One of the reasons for this fatal outcome in spite of treatment is that the liver has not only a detoxifying and a metabolic function, but also an excretory function. None of the bionic livers developed up to now have addressed this matter.
Another problem in relation to bionic livers is the difficulty of ensuring the cells' attachment to the surface of encapsulating systems, either capillaries or microcapsules (25, 26) . Attachment and spreading are both influenced by the nature of the membrane (27) . Linking anchoring molecules to the membrane, such as fibronectin or lam in in, might be of pivotal importance (28) .
In conclusion, the first steps in the direction of a bionic artificial liver have been taken. Further im-
